iTRAQ detects eEF1A1 as a candidate biomarker for Metastatic Progression of Prostate Cancer
ITSI-Biosciences’ latest newsflash publication, “iTRAQ detects eEF1A1 as a candidate biomarker for Metastatic Progression of Prostate Cancer” discusses how PSA is plagued with controversies and is unreliable because of its potential to provide false positive and false negative results. Hence additional biomarkers are needed to replace or compliment PSA to improve detection, diagnosis and prognostication of prostate cancer.